Zacks Research Issues Negative Outlook for Novavax Earnings

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Zacks Research dropped their Q1 2025 EPS estimates for shares of Novavax in a report released on Monday, April 14th. Zacks Research analyst S. Ganoria now forecasts that the biopharmaceutical company will post earnings per share of ($0.43) for the quarter, down from their previous forecast of ($0.42). The consensus estimate for Novavax's current full-year earnings is ($1.46) per share. Zacks Research also issued estimates for Novavax's FY2025 earnings at ($0.48) EPS, Q1 2026 earnings at ($0.13) EPS and Q3 2026 earnings at ($0.10) EPS.

Several other research firms have also commented on NVAX. TD Cowen raised Novavax to a "hold" rating in a report on Thursday, February 27th. BTIG Research started coverage on Novavax in a report on Friday, February 28th. They issued a "buy" rating and a $19.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Novavax presently has an average rating of "Hold" and a consensus price target of $18.00.

Novavax Stock Up 1.7 %

NASDAQ NVAX traded up $0.11 on Thursday, hitting $6.12. 1,198,187 shares of the stock were exchanged, compared to its average volume of 4,830,523. Novavax has a fifty-two week low of $3.90 and a fifty-two week high of $23.86. The company has a 50-day moving average price of $7.23 and a 200-day moving average price of $8.49. The company has a market cap of $983.56 million, a PE ratio of -2.71, a PEG ratio of 2.85 and a beta of 3.15.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.24. The company had revenue of $88.31 million for the quarter, compared to analysts' expectations of $85.48 million. During the same quarter last year, the company earned ($1.44) EPS.

Institutional Trading of Novavax

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new position in Novavax in the 4th quarter valued at $27,000. Spire Wealth Management acquired a new stake in shares of Novavax in the 4th quarter valued at approximately $29,000. New Age Alpha Advisors LLC acquired a new position in Novavax during the fourth quarter worth $35,000. KBC Group NV lifted its holdings in Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock valued at $64,000 after acquiring an additional 3,917 shares during the period. Finally, GAMMA Investing LLC increased its holdings in shares of Novavax by 2,272.5% in the 1st quarter. GAMMA Investing LLC now owns 11,839 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 11,340 shares in the last quarter. 53.04% of the stock is owned by hedge funds and other institutional investors.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.